Kathmere Capital Management LLC Acquires New Position in Pfizer Inc. (NYSE:PFE)

Kathmere Capital Management LLC purchased a new stake in shares of Pfizer Inc. (NYSE:PFE) during the second quarter, Holdings Channel.com reports. The firm purchased 7,266 shares of the biopharmaceutical company’s stock, valued at approximately $266,000.

A number of other hedge funds have also recently made changes to their positions in the business. Front Street Capital Management Inc. grew its stake in shares of Pfizer by 4.3% in the first quarter. Front Street Capital Management Inc. now owns 5,168 shares of the biopharmaceutical company’s stock valued at $268,000 after buying an additional 215 shares in the last quarter. Synergy Asset Management LLC grew its position in Pfizer by 3.3% in the 4th quarter. Synergy Asset Management LLC now owns 7,287 shares of the biopharmaceutical company’s stock valued at $373,000 after acquiring an additional 236 shares in the last quarter. Motco increased its stake in Pfizer by 0.8% during the fourth quarter. Motco now owns 31,376 shares of the biopharmaceutical company’s stock worth $1,608,000 after purchasing an additional 236 shares during the period. OLD Point Trust & Financial Services N A lifted its position in shares of Pfizer by 0.5% during the fourth quarter. OLD Point Trust & Financial Services N A now owns 49,152 shares of the biopharmaceutical company’s stock worth $2,519,000 after purchasing an additional 250 shares in the last quarter. Finally, Confluence Wealth Services Inc. boosted its stake in shares of Pfizer by 0.5% in the fourth quarter. Confluence Wealth Services Inc. now owns 55,282 shares of the biopharmaceutical company’s stock valued at $2,833,000 after purchasing an additional 252 shares during the period. 68.05% of the stock is currently owned by institutional investors.

Wall Street Analyst Weigh In

A number of research firms have issued reports on PFE. BMO Capital Markets reduced their target price on shares of Pfizer from $45.00 to $44.00 and set an “outperform” rating on the stock in a report on Wednesday, August 2nd. Cantor Fitzgerald reissued an “overweight” rating and set a $75.00 target price on shares of Pfizer in a research note on Tuesday, September 5th. Barclays reduced their price target on Pfizer from $40.00 to $38.00 in a research report on Tuesday, July 11th. StockNews.com began coverage on Pfizer in a research report on Thursday, August 17th. They set a “hold” rating for the company. Finally, Credit Suisse Group cut shares of Pfizer from an “outperform” rating to a “neutral” rating and reduced their target price for the company from $47.00 to $40.00 in a report on Thursday, June 29th. Twelve analysts have rated the stock with a hold rating and five have assigned a buy rating to the company’s stock. According to MarketBeat.com, the company has an average rating of “Hold” and an average price target of $46.35.

Pfizer Trading Down 0.2 %

NYSE PFE opened at $34.07 on Monday. The firm’s fifty day moving average is $35.80 and its two-hundred day moving average is $37.96. Pfizer Inc. has a one year low of $33.54 and a one year high of $54.93. The company has a debt-to-equity ratio of 0.62, a quick ratio of 1.82 and a current ratio of 2.12. The firm has a market cap of $192.36 billion, a PE ratio of 9.06, a P/E/G ratio of 1.14 and a beta of 0.59.

Pfizer (NYSE:PFE) last announced its quarterly earnings data on Tuesday, August 1st. The biopharmaceutical company reported $0.67 EPS for the quarter, topping analysts’ consensus estimates of $0.57 by $0.10. Pfizer had a net margin of 27.55% and a return on equity of 28.36%. The company had revenue of $12.73 billion during the quarter, compared to the consensus estimate of $13.36 billion. During the same quarter in the prior year, the firm earned $2.04 EPS. Pfizer’s quarterly revenue was down 54.1% on a year-over-year basis. Analysts expect that Pfizer Inc. will post 3.33 earnings per share for the current year.

Pfizer Announces Dividend

The firm also recently disclosed a quarterly dividend, which was paid on Tuesday, September 5th. Investors of record on Friday, July 28th were issued a dividend of $0.41 per share. This represents a $1.64 dividend on an annualized basis and a yield of 4.81%. The ex-dividend date was Thursday, July 27th. Pfizer’s dividend payout ratio is presently 43.62%.

Pfizer Company Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.